According to the guideline of the National Institute on Aging and Alzheimer's Association in 2011, the biomarkers for AD can be classified into three categories: β amyloid deposition (Aβ), pathologic tau, and neurodegeneration [AT(N)]5. This evidence concerns the gene MAPT and Alzheimer disease.